India Waives Large-Scale Trials For Sanofi’s Dengue Vaccine
This article was originally published in PharmAsia News
Executive Summary
An Indian panel has recommended the government dispense with Phase III trials for Sanofi's vaccine to prevent dengue after last year's major domestic outbreak of the virus caused by the same mosquito responsible for the current spread of Zika disease. The decision comes as India gears up to tackle the new threat from Zika.